Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib With or Without Trastuzumab in HER2-positive Advanced Colorectal Cancer
NCT04380012Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of pyrotinib in colorectal cancer (CRC) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04380012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380012.